---
title: "BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276854079.md"
description: "Tyler Van Buren from TD Cowen has maintained a Buy rating on BridgeBio Pharma with a price target of $95.00. He cites strong commercial execution and the successful launch of Attruby, which has exceeded sales expectations. The company’s late-stage pipeline, including three Phase III programs and planned NDA filings, positions it for potential blockbuster growth and cash-flow positivity by late 2027. Bank of America Securities also supports a Buy rating with a $97.00 target."
datetime: "2026-02-25T08:15:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276854079.md)
  - [en](https://longbridge.com/en/news/276854079.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276854079.md)
---

# BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on BridgeBio Pharma. The associated price target remains the same with $95.00.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Tyler Van Buren has given his Buy rating due to a combination of factors tied to BridgeBio’s strong commercial and clinical execution. He points to the robust launch of Attruby, where quarterly and full-year sales have exceeded expectations, and prescription trends show accelerating uptake across a broad base of prescribers, supporting a sustained growth profile into 2026.

He also emphasizes that three successful Phase III programs and multiple planned NDA filings through 2026 create several potential blockbuster drivers that can transform the company’s earnings power. In his view, this pipeline, combined with rising Attruby revenues, positions BridgeBio to turn cash-flow positive by late 2027 and evolve into a durable cash generator from 2028 onward, justifying a Buy recommendation on the shares.

Van Buren covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and BridgeBio Pharma. According to TipRanks, Van Buren has an average return of 21.7% and a 55.14% success rate on recommended stocks.

In another report released on February 18, Bank of America Securities also maintained a Buy rating on the stock with a $97.00 price target.

### Related Stocks

- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Aligos Therapeutics (ALGS) Gets a Buy from H.C. Wainwright](https://longbridge.com/en/news/283864894.md)
- [Sagimet Highlights Pipeline Progress and Strategic Corporate Developments](https://longbridge.com/en/news/284209078.md)
- [Fulcrum Therapeutics Q1 net loss widens on higher expenses](https://longbridge.com/en/news/284202157.md)
- [AbbVie beats Q1 revenue, profit estimates on Skyrizi, Rinvoq demand; lifts profit outlook](https://longbridge.com/en/news/284564851.md)
- [Pulse Biosciences Reports Strong nPulse Atrial Fibrillation Data](https://longbridge.com/en/news/284232599.md)